Clinical trial
Clinical Trial for Ovarian Cancer (OvaRex®)
NCT00050375 · Unither Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00050375 |
|---|---|
| Title | Clinical Trial for Ovarian Cancer (OvaRex®) |
| Official title | A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex® MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin |
| Lead sponsor | Unither Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | oregovomab |
| Enrollment | 354 |
| Start date | Dec 1, 2002 |
| Completion | Dec 1, 2007 |
| First posted | Dec 6, 2002 |
| Last update posted | Dec 18, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: